COVID-19 highlights why we must commit to breaking down barriers to patient diversity in research

21 August 2020

Media headlines are full of hope for potential vaccines and treatments to target SARS-CoV-2, the virus that causes the novel coronavirus disease COVID-19, writes Kate Shaw, the chief executive of UK-based clinical trials patient recruitment company Innovative Trials, in an Expert View.

There are almost 200 vaccine candidates currently in development and research is reported to be progressing well. Deals have already been agreed between some pharmaceutical companies and the UK government to supply stocks of potential medicines.

These are certainly reasons to be optimistic, but in this race for effective treatments and vaccines, one issue remains the metaphorical elephant in the room: patient diversity. Or,
more appropriately, the lack of it.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK